Yelp ranks top chicken sandwich chains; two Georgia spots make the cut
Chick-fil-A started in a small diner in Hapeville, Georgia and is now known across the country for making great chicken.
"Chick-fil-A is famous for its simple, perfectly seasoned chicken sandwich served on a toasted buttered bun," Yelp wrote. "Simple? Yes. Iconic? Absolutely."
Who founded Chick-fil-A?
The trio behind Chick-Fil-A is the Cathy family and siblings are Bubba, Dan, and Trudy. The first location opened in 1967 at Atlanta's Greenbriar Mall.
The chain has more than 2,800 restaurants across the U.S. and in Canada and Puerto Rico.
Chick-fil-A is also "known for its consistency, customer service and loyal fanbase," Yelp wrote.
But this isn't the only Georgia-founded favorite that landed on the list. Founded in Statesboro, Zaxby's ranked No. 10 in the nation.
Who founded Zaxby's?
Tony Townley and Zach McLeroy, both 62-years-old, started this food chain in 1990. Zaxby's corporate location is in Athens, where the two grew up and met in the seventh grade.
"Zaxby's is known for bold sauces, crispy chicken, and its crave-worthy Zax sauce," Yelp wrote. "When the brand entered the chicken sandwich wars in 2021 with its Signature Sandwich, it brought the same flavor-forward approach to a handheld format."
Here are all other Yelp rankings.
Yelp's top 20 chicken sandwich chains of 2025
Chick-fil-A
Dave's Hot Chicken
Raising Cane's
Shake Shack
Popeyes Louisiana Kitchen
Habit Burger and Grill
Denny's
Wingstop
McDonald's
Zaxby's
Jack in the Box
Dairy Queen
Slim Chickens
Burger King
Wendy's
Sonic Drive-In
Bojangles
KFC
Arby's
Church's Chicken
Whether you like it spicy, grilled, or covered in Chick-fil-A sauce, Georgia's favorite chicken spot is still leading the way.
Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@gannett.com.
This article originally appeared on Savannah Morning News: Yelp ranks top chicken sandwich chains, two Georgia spots make the cut
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Jim Cramer Says Nutex 'Might Need a New Catalyst' to See More Upside
Nutex Health Inc. (NASDAQ:NUTX) is one of the stocks that Jim Cramer shed light on. While Cramer acknowledged that the company has an 'interesting story,' he said: '… Why is the stock coming in over the past couple of months? Well, after a modest pullback in late May, Nutex started pulling back hard in the first week of June, ultimately falling more than 27% that week. Towards the end of that week, an analyst at Benchmark wrote a note explaining that the pullback was because of Blue Cross Blue Shield of Georgia filing a lawsuit against two physician provider groups that are using that same arbitration process that Nutex has had so much success with. Pixabay/Public domain Nutex Health (NASDAQ:NUTX) is a physician-led healthcare company that manages micro-hospitals, specialty hospitals, and outpatient departments offering 24/7 care. The company provides emergency and inpatient services, behavioral health, diagnostic imaging, laboratory testing, pharmacy services, and administrative support to affiliated healthcare providers through a cloud-based platform. While we acknowledge the potential of NUTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
14 minutes ago
- Associated Press
Alora Healthcare Systems Earns CHAP Verified Status for Home Health, Hospice, and Home Care Software
ATLANTA, July 23, 2025 /PRNewswire/ -- Alora Healthcare Systems, a leading provider of cloud-based solutions for post-acute care, announced this week that its full suite of software solutions – Home Health, Hospice, and Home Care, has earned CHAP Verified status from CHAP, Inc. (Community Health Accreditation Partner). This designation confirms that Alora's solutions meet CHAP's highest standards in operational excellence, compliance, and quality improvement. The verification process included a detailed review of Alora's functionality and alignment with CHAP's Standards of Excellence. CHAP verified that Alora's software fully supports compliance and actively enhances care delivery. 'The Alora team consistently delivers impressive software across Home Health, Hospice, and Home Care, marked by its user-friendly interface, extensive customization options, and powerful tools for operations and compliance,' stated Teresa Harbour, Chief Operating Officer of CHAP, Inc. 'Their dedication to listening to customer feedback is evident in continuous enhancements like the OASIS-E analyzer, real-time reporting, and integrated HR and billing platforms, all designed to meet individual care needs and regulatory requirements efficiently,' she added. CHAP Verified status highlights Alora's ability to support agencies in achieving compliance while advancing post-acute care technology. The platform is designed for efficiency, enabling high-quality, patient-centered care amid a changing regulatory landscape. Sathish John, CEO of Alora, remarked, 'This achievement is a direct reflection of our mission to simplify workflows for clinicians, administrators, and caregivers, while focusing on compliance, quality, and feedback.' Alora's comprehensive platform includes tools for documentation, billing, scheduling, visit verification, compliance, HR, and more, providing a streamlined experience for both skilled and non-skilled care. This recognition strengthens Alora's commitment to empowering home-based care agencies with CHAP Verified solutions that drive excellence and regulatory confidence. About Alora Alora is a leading provider of cloud-based home care software, home health software, and hospice software, for agencies across the U.S. Known for its intuitive interface and award-winning support, Alora delivers robust, integrated tools that empower agencies to streamline operations, ensure compliance, and focus on patient care. About CHAP CHAP is the nation's first accrediting body for home and community-based healthcare organizations. As an independent, nonprofit accrediting body, CHAP advances the highest standards of community-based care. Media Contact: Alora Healthcare Systems [email protected] 800-954-8250 Website: View original content: SOURCE Alora Healthcare Systems
CNN
44 minutes ago
- CNN
Trump says he is ‘thinking about' nixing capital gains tax on home sales. Here's what that could mean for homeowners
In comments to the press on Tuesday, President Donald Trump suggested he is considering eliminating capital gains taxes on the sale of homes. 'We are thinking about … no tax on capital gains on houses,' Trump said. Soon afterwards, Rep. Marjorie Taylor Greene of Georgia posted her thanks to him on X for what she interpreted to be his support for a bill she introduced this month, calling for the elimination of the capital gains tax when someone sells their primary residence. Will anything come of it? Who knows. Especially since Trump just signed into law a mega tax-and-spending cuts bill that the Congressional Budget Office estimates will increase deficits on net by $3.4 trillion over a decade while at the same time knocking 10 million more people off health insurance. But should it become an idea that Congress pursues seriously, it's worth reviewing just how the capital gains tax on home sales works currently and who might benefit most if it were killed. If you sell a primary residence on which you realize a big capital gain — meaning you sell it for more than you bought it even after accounting for closing fees and qualified home improvement costs along the way — you may owe a capital gains tax on at least some of that gain. Or not. It depends. If you sell your house within a year of buying it, any capital gains will be considered short-term and you will have to pay ordinary income tax on all your gains. But if you have lived in it as your primary residence for at least 24 months (consecutively or not) in the previous five years before you sell it, you may be allowed to exempt from the capital gains tax the first $250,000 of your gains if you're single or $500,000 if you're married filing jointly Any gains above those thresholds are subject to the long-term capital gains tax. But just how much you'll pay is based on your income, broken out below. You also may get a break on the capital gains tax if you don't meet the eligibility tests but had to sell your home 'due to a change in employment, health, or unforeseen circumstances,' according to the IRS. (Note, too, that the capital gains tax rules work somewhat differently when you sell a second home or rental property.) In 2025, filers will owe 0% in capital gains tax for gains above the exemption threshold if their taxable income is below $48,350 (or $96,700 if married filing jointly), according to the IRS. They will owe 15% if their income is between $48,450 and $533,400 (or between $96,700 and $600,050 for joint filers). And any filer with income above those levels will pay a 20% capital gains rate. In all instances, however, the long-term capital gains tax rate is often below the top ordinary income tax rate a filer faces. Since the $250,000 and $500,000 capital gains exemption thresholds have not adjusted for inflation since they were set in 1997, a growing number of homeowners, especially long-time ones, may realize taxable gains even if they don't live in the highest-priced areas by today's standards. Generally speaking, three categories of home sellers are the ones most likely to have to pay the capital gains tax if they make out well selling their home: 1) Anyone living in an area where homes have appreciated greatly in recent years, especially in neighborhoods where home prices are typically well above the national average; 2) anyone who has lived in their home for decades during which time nominal home prices have shot up; or 3) anyone with high income and sufficient wealth to buy a very expensive home wherever they live. A recent study by the National Association of Realtors, which has advocated for doubling the exemption caps and adjusting them as if they'd been indexed to inflation since 1997, estimates that 29 million homeowners — about one-third — may already have enough equity in their home to exceed the $250,000 cap, while 8 million — or about one-tenth — may have enough to top the $500,000 threshold. Looking ahead, it forecasts that by 2035, close to 70% of homeowners might have gains exceeding $250,000 and 38% of them will have more than $500,000. 'In states with exceptionally high-priced markets, such as California, Massachusetts and Colorado, the trend is even more pronounced,' the report said. Broadly speaking, NAR contends, the current caps may be disincentivizing homeowners to sell. 'Over the past 28 years, home price inflation has eroded the value of these exemptions, especially for older homeowners who have lived in their home for 20 years or more. At a time when many of these homeowners are considering downsizing or moving to a retirement facility, more and more are facing gains well in excess of the exclusions, which can leave them owing many thousands of dollars in taxes and reduce their ability to afford a new home.' In another analysis, the Yale Budget Lab, using the Federal Reserve's 2022 Survey of Consumer Finances, noted that the minority of homeowners who might currently benefit if the capital gains tax were eliminated are largely wealthier, higher-income, and older on average. 'In 2022, homeowners with gains above the exemption had an average net worth of $5.7 million. For homeowners below the exemption, this number was just over $1 million,' the researchers wrote.
